communityacquir
pneumonia
seventh
lead
caus
death
overal
common
caus
death
infecti
diseas
unit
state
base
clinic
condit
patient
admit
medic
ward
sever
ill
icu
icu
patient
carri
highest
mortal
rate
among
patient
cap
multipl
set
clinic
practic
guidelin
publish
past
year
address
treatment
cap
agre
cap
patient
admit
hospit
repres
major
concern
appropri
empir
therapi
institut
improv
clinic
outcom
review
current
literatur
relat
cap
patient
admit
icu
regard
epidemiolog
risk
factor
sever
criteria
reason
admit
hospit
patient
icu
empir
specif
antibiot
therapeut
regimen
employ
sever
cap
defin
clinic
syndrom
develop
patient
pneumonia
requir
hospit
ward
servic
andor
icu
year
million
patient
hospit
unit
state
death
attribut
cap
influenza
estim
cost
approxim
nine
billion
dollar
per
year
approxim
hospit
patient
requir
icu
admiss
hospit
cap
patient
carri
signific
mortal
depend
sever
ill
sever
studi
report
mortal
rate
approxim
hospit
ward
patient
mortal
patient
requir
icu
admiss
cap
burdensom
health
care
system
durat
hospit
day
cost
approxim
ward
patient
compar
day
icu
patient
import
determin
hospit
assess
sever
cap
patient
chronic
comorbid
condit
andor
prior
antibiot
use
see
tabl
prior
antibiot
use
defin
cap
clinic
practic
guidelin
use
antibiot
regim
past
month
also
associ
increas
risk
morbid
mortal
common
comorbid
ill
cap
patient
chronic
obstruct
pulmonari
diseas
copd
present
half
patient
follow
alcohol
chronic
heart
diseas
diabet
mellitu
tabl
show
risk
factor
associ
microorgan
import
point
approxim
onethird
patient
cap
previous
healthi
elderli
nurs
home
patient
also
signific
risk
cap
high
mortal
rate
although
expert
consid
pneumonia
nurs
home
patient
health
care
associ
pneumonia
due
similar
etiolog
pathogen
hospit
acquir
pneumonia
hospit
rate
pneumonia
increas
among
us
adult
age
year
age
year
past
year
among
age
year
older
least
patient
hospit
year
due
pneumonia
main
caus
death
sever
cap
patient
includ
refractori
hypoxemia
refractori
shock
pneumoniarel
complic
predominantli
multiorgan
failur
microbi
pattern
sever
cap
extens
studi
past
decad
consist
streptococcu
pneumonia
recogn
common
pathogen
caus
cap
respiratori
gnr
gramneg
rod
hcap
health
care
associ
pneumonia
mssa
methicillinsuscept
aureu
mrsa
methicillinresist
aureu
rsv
respiratori
syncyti
viru
includ
renal
failur
chronic
renal
diseas
neurolog
diseas
cerebrovascular
diseas
malnutrit
hepat
diseas
chronic
liver
diseas
bacteremia
smoke
histori
gross
aspir
tabl
howev
extens
list
pathogen
associ
sever
cap
icu
associ
individu
pathogen
certain
comorbid
condit
mention
earlier
tabl
specif
treatment
discuss
end
chapter
one
critic
decis
physician
treat
patient
cap
whether
hospit
patient
ward
icu
servic
decis
usual
made
outpati
offic
emerg
depart
implic
antibiot
class
select
rout
durat
therapi
two
tool
develop
predict
mortal
determin
site
care
patient
cap
base
sever
ill
pneumoniaspecif
sever
ill
psi
score
curb
rule
fine
colleagu
develop
psi
score
part
pneumonia
patient
outcom
research
team
studi
port
psi
base
paramet
includ
three
demograph
variabl
five
presenc
least
one
major
criterion
least
two
minor
criteria
defin
pneumonia
sever
enough
requir
icu
admiss
ed
modifi
at
criteria
sever
cap
investig
includ
presenc
one
two
major
criteria
andor
two
three
minor
criteria
tabl
sever
studi
valid
criteria
admit
patient
icu
appli
also
group
patient
includ
elderli
hivinfect
patient
thu
sever
assess
criteria
use
help
physician
identifi
patient
may
need
hospit
icu
admiss
meant
remov
physician
clinic
judgment
decisionmak
process
patient
suspect
cap
receiv
chest
radiograph
confirm
diagnosi
pneumonia
sever
laboratori
studi
perform
patient
cap
admit
icu
order
assess
sever
diseas
possibl
complic
test
includ
complet
blood
cell
count
differenti
basic
blood
chemistri
urea
nitrogen
serum
creatinin
electrolyt
sodium
potassium
glucos
liver
function
test
evalu
oxygen
puls
oxymetri
arteri
blood
ga
analysi
extrem
import
mandatori
attempt
obtain
sampl
identifi
like
etiolog
agent
indic
sever
cap
patient
howev
support
evid
microbiolog
studi
chang
favor
final
outcom
patient
sever
microbiolog
test
recommend
patient
cap
icu
tabl
addit
diagnost
marker
includ
creactiv
protein
crp
andor
procalcitonin
use
prognost
indic
variabl
result
treatment
guidelin
develop
sever
profession
organ
standard
therapi
sever
communityacquir
pneumonia
icu
cap
includ
patient
sever
cap
publish
practic
guidelin
reflect
evolut
expert
opinion
chang
resist
pattern
avail
new
clinic
data
regard
treatment
diagnosi
cap
manag
immunocompet
adult
guidelin
support
concept
treatment
icu
patient
cap
focus
possibl
associ
etiolog
agent
appropri
aggress
earli
therapeut
approach
includ
initi
antibiot
cover
macrolid
fluoroquinolon
mix
infect
typic
atyp
pathogen
occur
approxim
case
alway
consid
ensur
patient
treat
appropri
empir
antimicrobi
therapi
case
infect
pathogen
identifi
direct
therapi
employ
clinic
seri
approxim
patient
cap
pathogen
identifi
failur
identifi
pathogen
associ
wors
outcom
empir
regimen
cover
pneumonia
atyp
pathogen
clinic
practic
guidelin
suggest
sever
cap
patient
admit
icu
stratifi
whether
patient
risk
pseudomona
spp
infect
patient
risk
factor
pseudomona
infect
treatment
alway
includ
two
antibiot
one
betalactam
cover
pneumococcu
includ
drug
resist
isol
anoth
macrolid
respiratori
fluoroquinolon
cover
atyp
pathogen
especi
legionella
spp
tabl
pseudomona
aeruginosa
report
sever
cap
patient
specif
risk
factor
chronic
prolong
use
broadspectrum
antibiot
therapi
bronchiectasi
malnutrit
hiv
immunosuppress
patient
risk
factor
p
aeruginosa
admit
icu
requir
specif
attent
receiv
appropri
antipseudomon
agent
discuss
tabl
two
random
control
trial
sever
observ
studi
evalu
benefit
use
combin
therapi
versu
monotherapi
patient
sever
cap
admit
icu
limit
data
signific
heterogen
studi
conclud
limit
inform
compar
differ
mortal
patient
cap
icu
hand
strong
evid
support
clinic
practic
guidelin
demonstr
statist
signific
benefit
patient
receiv
guidelin
concord
therapi
patient
cap
addit
data
support
benefit
use
combin
therapi
betalactam
agent
plu
macrolid
initi
empir
therapi
reduc
mortal
patient
cap
sever
studi
suggest
benefit
macrolid
ad
betalactam
therapi
patient
bacterem
pneumococc
pneumonia
ad
macrolid
betalactam
base
initi
antibiot
regimen
independ
predictor
inhospit
mortal
specif
antimicrobi
therapi
identifi
cap
pathogen
describ
tabl
gener
durat
therapi
patient
sever
cap
day
atyp
pathogen
legionella
spp
receiv
longer
treatment
day
sever
studi
report
use
critic
pathway
improv
treatment
cap
patient
includ
sever
diseas
antimicrobi
treatment
failur
nonresolv
pneumonia
usual
underestim
common
caus
includ
microbi
resist
initi
antimicrobi
regimen
suppur
complic
presenc
nosocomi
pneumonia
initi
clinic
improv
hospit
patient
switch
intraven
oral
antibiot
therapi
maintain
similar
antimicrobi
coverag
tissu
concentr
parenter
form
criteria
determin
patient
make
transit
oral
antibiot
includ
abil
toler
antibiot
mouth
function
gastrointestin
tract
stabl
blood
pressur
trend
toward
normal
white
blood
cell
count
improv
symptom
cough
dyspnea
fever
metaanalysi
rhew
et
al
evalu
earli
intraven
oral
convers
discharg
strategi
patient
cap
demonstr
intervent
associ
signific
safe
reduct
mean
length
hospit
stay
sever
qualiti
indic
alreadi
mention
earli
administr
antibiot
appropri
antibiot
use
follow
clinic
practic
guidelin
use
critic
pathway
switch
oral
therapi
earli
discharg
show
improv
clinic
outcom
cap
addit
measur
direct
prevent
vaccin
pneumococc
influenza
infect
counsel
quit
smoke
patient
risk
may
help
decreas
incid
cap
import
process
care
includ
collect
blood
cultur
antibiot
administr
first
h
test
legionella
infect
icu
patient
evalu
oxygen
measur
blood
gase
puls
oximetri
describ
diagnosi
antibiot
treatment
acut
exacerb
chronic
obstruct
pulmonari
diseas
aecopd
chronic
obstruct
pulmonari
diseas
copd
condit
associ
aecopd
copd
current
account
approxim
death
per
year
make
follow
heart
diseas
cancer
stroke
fourth
lead
caus
death
unit
state
estim
year
aecopd
third
lead
caus
death
cost
treat
aecopd
high
econom
impact
also
high
associ
morbid
earli
mortal
copd
unit
state
annual
account
offic
visit
hospit
billion
dollar
direct
health
care
cost
despit
treatment
antibiot
bronchodil
corticosteroid
patient
discharg
emerg
depart
acut
exacerb
recurr
symptom
within
day
relaps
requir
hospit
sever
investig
confirm
relaps
like
among
patient
lower
pretreat
posttreat
fev
receiv
bronchodil
treatment
corticosteroid
visit
higher
rate
previou
relaps
aecopd
associ
signific
mortal
studi
understand
prognosi
prefer
outcom
rate
treatment
support
mortal
rate
mortal
rate
signific
predictor
mortal
includ
acut
physiolog
chronic
health
evalu
apach
iii
score
bodi
mass
index
age
function
statu
week
prior
admiss
lower
ratio
pao
f
congest
heart
failur
serum
albumin
level
cor
pulmonal
lower
activ
daili
live
score
lower
score
duke
activ
statu
index
number
hospit
day
transfer
icu
although
respiratori
infect
assum
main
risk
factor
exacerb
copd
factor
also
involv
mani
patient
aecopd
thought
combin
viral
bacteri
infect
contribut
exacerb
varieti
microorgan
shown
associ
infecti
bacteri
aecopd
includ
haemophilu
influenza
h
parainfluenza
moraxella
catarrhali
streptococcu
pneumonia
also
report
patient
may
infect
atyp
pathogen
mycoplasma
pneumonia
chlamydia
pneumonia
limit
diagnosi
true
preval
organ
known
sever
recent
studi
demonstr
patient
sever
copd
requir
icu
care
significantli
higher
preval
gramneg
organ
enterobacteriacea
pseudomona
speci
sever
investig
propos
airway
damag
chronic
infect
colon
occur
patient
bacteria
caus
host
continu
releas
inflammatori
mediat
persist
infect
result
lung
inflamm
consequ
lung
function
progress
decreas
recent
evid
base
analysi
summar
best
avail
inform
relat
use
diagnost
test
aecopd
review
conclud
data
util
diagnost
test
limit
howev
chest
radiographi
arteri
blood
ga
sampl
use
spirometri
perform
time
exacerb
patient
requir
icu
care
chest
radiograph
obtain
order
rule
abnorm
arteri
blood
gase
number
clinic
trial
examin
use
antibiot
treatment
aecopd
gold
guidelin
gold
websit
access
feb
american
thorac
societyeuropean
respiratori
societi
atser
copd
consensu
guidelin
recommend
antibiot
choic
basi
local
sensit
pattern
common
pathogen
associ
aecopd
provid
specif
guidelin
limit
number
studi
look
use
antibiot
icu
patient
recent
public
includ
recent
metaanalysi
demonstr
benefit
antibiot
acut
exacerb
ambulatori
patient
studi
anthonisen
et
al
report
patient
three
clinic
symptom
increas
short
breath
increas
sputum
product
chang
sputum
purul
initi
present
receiv
antibiot
show
rapid
improv
peak
flow
greater
percentag
clinic
success
smaller
percentag
clinic
failur
receiv
placebo
furthermor
allegra
et
al
found
signific
benefit
use
amoxicillinclavulan
acid
augmentin
therapi
compar
placebo
patient
sever
diseas
patient
receiv
antibiot
exhibit
higher
success
rate
versu
placebo
group
p
lower
frequenc
recurr
exacerb
one
studi
evalu
role
antibiot
aecopd
icu
patient
nouira
et
al
publish
prospect
random
doubleblind
placebocontrol
trial
evalu
use
ofloxacin
patient
aecopd
requir
mechan
ventil
invas
noninvas
studi
demonstr
signific
number
gramneg
organ
includ
e
coli
p
mirabili
p
aeruginosa
identifi
popul
patient
sever
aecopd
addit
support
find
previous
report
studi
trial
demonstr
treat
pathogen
import
improv
outcom
highrisk
popul
antibiotictr
group
significantli
lower
inhospit
mortal
rate
significantli
reduc
length
stay
hospit
compar
placebo
group
addit
patient
receiv
ofloxacin
less
like
develop
pneumonia
placebo
addit
potenti
benefit
antibiot
therapi
patient
aecopd
antibiot
reduc
burden
bacteria
airway
larg
percentag
patient
acut
exacerb
potenti
pathogen
microorgan
addit
significantli
higher
concentr
frequent
organ
bacteria
larg
airway
treatment
appropri
antibiot
significantli
decreas
bacteri
burden
followup
bronchoscopi
specul
proper
choic
antibiot
reduc
risk
progress
sever
infect
pneumonia
erad
bacteria
antibiot
thought
break
viciou
cycl
infect
ie
lung
destruct
lead
progress
lung
diseas
use
antibiot
treat
aecopd
potenti
benefit
discuss
matter
agent
chosen
anthonisen
et
al
studi
assumpt
made
antibiot
equival
thu
specif
agent
prescrib
consid
import
despit
problem
mani
publish
antibiot
trial
retrospect
trial
emphas
import
choos
correct
antibiot
treatment
patient
aecopd
recent
retrospect
studi
outpati
document
copd
conduct
institut
evalu
risk
factor
therapi
failur
day
acut
exacerb
one
group
patient
receiv
antibiot
second
group
overal
relaps
rate
defin
return
visit
persist
worsen
symptom
within
day
extens
multivari
analysi
major
risk
factor
relaps
lack
antibiot
therapi
versu
p
compar
antibi
otictr
group
type
antibiot
use
also
import
variabl
associ
treatment
failur
patient
treat
amoxicillin
relaps
rate
compar
antibiot
p
furthermor
treatment
amoxicillin
result
higher
incid
failur
even
compar
receiv
antibiot
includ
amoxicillin
macrolid
ciprofloxacin
p
although
may
mani
explan
treatment
failur
like
pathogen
resist
amoxicillin
studi
show
use
antibiot
associ
significantli
lower
rate
therapi
failur
contrast
anthonisen
data
adam
data
show
antibiot
benefici
regardless
sever
aecopd
furthermor
patient
receiv
antibiot
fail
within
day
significantli
higher
rate
hospit
admiss
receiv
antibiot
destach
et
al
report
impact
antibiot
select
antimicrobi
efficaci
relat
cost
aecopd
failur
rate
significantli
higher
day
firstlin
amoxicillin
cotrimoxazol
erythromycin
tetracyclin
compar
thirdlin
amoxicillinclavulan
azithromycin
ciprofloxacin
agent
versu
p
compar
receiv
firstlin
agent
patient
treat
thirdlin
agent
significantli
longer
time
exacerb
overal
fewer
hospit
consider
lower
total
cost
convent
endpoint
efficaci
antibiot
treatment
aecopd
includ
symptom
bacteriolog
resolut
measur
week
treatment
start
endpoint
reli
sole
subject
report
symptom
improv
suggest
sever
investig
paramet
rate
symptom
resolut
interv
exacerb
improv
qualiti
life
need
hospit
mortal
may
suitabl
endpoint
patient
popul
clinic
paramet
implic
possibl
risk
factor
treatment
failur
aecopd
suggest
therapi
summar
tabl
two
import
prevent
measur
aecopd
cap
patient
smoke
cessat
activ
immun
includ
influenza
pneumococc
vaccin
influenza
import
caus
lower
respiratori
tract
infect
influenza
b
often
reach
epidem
proport
winter
month
impact
influenza
critic
develop
lower
respiratori
infect
includ
aecopd
pneumonia
epidemiolog
studi
shown
frequenc
lower
respiratori
infect
associ
morbid
mortal
markedli
reduc
influenza
vaccin
polyval
vaccin
base
pneumococc
capsul
serotyp
shown
effect
prevent
pneumococc
bacteremia
pneumonia
vaccin
recommend
patient
copd
cost
morbid
mortal
relat
cap
aecopd
remain
unaccept
high
heterogen
group
patient
import
use
riskstratif
base
clinic
paramet
predict
tool
appropri
antibiot
therapi
import
compon
manag
group
patient
particular
essenti
administ
appropri
antimicrobi
agent
initi
therapi
risk
treatment
failur
morbid
cap
aecopd
may
minim
